Patents by Inventor Pascal Furet

Pascal Furet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INTERLEUKIN-17 INHIBITORS
    Publication number: 20230391782
    Abstract: The present invention relates to novel pyridine-N oxide substituted 2-formamido (N-phenyl and N-pyridyl) acetamide compounds that are Interleukin-17 (IL-17) inhibitors, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by IL-17.
    Type: Application
    Filed: November 1, 2021
    Publication date: December 7, 2023
    Inventors: Thomas Josef TROXLER, David ORAIN, Pascal FURET, Klaus WEIGAND, Achim SCHLAPBACH
  • BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS
    Publication number: 20210299100
    Abstract: The present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: March 15, 2021
    Publication date: September 30, 2021
    Inventors: Vincent BORDAS, Cara BROCKLEHURST, Patrick CHENE, Zhongbo FEI, Pascal FURET, Vito GUAGNANO, Patricia IMBACH-WEESE, Joerg KALLEN, Mickael LE DOUGET, Jialiang LI, Wei LI, Edwige Liliane Jeanne LORTHIOIS, Joseph McKENNA, Bahaa SALEM, Tobias SCHMELZLE, Holger SELLNER, Nicolas SOLDERMANN, Markus VOEGTLE, Markus WARTMANN
  • Formylated N-heterocyclic derivatives as FGFR4 inhibitors
    Patent number: 10786492
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: September 29, 2020
    Assignee: NOVARTIS AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Thomas Knoepfel, Catherine Leblanc, Robert Mah
  • OXAZOLIDIN-2-ONE-PYRIMIDINE DERIVATIVES AND THE USE THEREOF AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS
    Publication number: 20190382399
    Abstract: The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.
    Type: Application
    Filed: December 18, 2018
    Publication date: December 19, 2019
    Inventors: Robin Alec Fairhurst, Pascal Furet, Frank Stephen Kalthoff, Andreas Lerchner, Heinrich Rueeger
  • Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
    Patent number: 10507201
    Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: December 17, 2019
    Assignee: NOVARTIS AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Diana Graus Porta, Carolina Haefliger, Bo Han, Thomas Knöpfel, Catherine Leblanc, Lv Liao, Robert Mah, Masato Murakami, Pierre Nimsgern, Michael Palmer, Dale Porter, Sebastien Ripoche, Can Wang, Youzhen Wang, Andreas Weiss, Jing Xiong, Xianglin Zhao
  • Heterocyclyl-substituted cyclohexylsulfonamides as JAK inhibitors
    Patent number: 10370375
    Abstract: The invention relates to a compound of formula (I) wherein the variables have the meaning as indicated in the claims; in free form and in salt form; and optionally the enantiomers and geometrical isomers thereof. The compounds of formula (I) are useful as therapeutic agent for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis. Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, inflammatory bowel diseases, Crohn's disease, Alzheimer's disease, leukemia, osteoarthritis, control of pruritus, chronic respiratory disease or keratoconjunctivitis in mammals.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: August 6, 2019
    Assignee: Elanco Tiergesundheit AG
    Inventors: Noelle Gauvry, Chouaib Tahtaoui, Pascal Furet, Pierre Ducray
  • USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS
    Publication number: 20190231760
    Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof
    Type: Application
    Filed: February 28, 2019
    Publication date: August 1, 2019
    Inventors: Nicole BUSCHMANN, Robin Alec FAIRHURST, Pascal FURET, Diana GRAUS PORTA, Carolina HAEFLIGER, Bo HAN, Thomas KNOPFEL, Catherine LEBLANC, Lv LIAO, Robert MAH, Masato MURAKAMI, Pierre NIMSGERN, Michael PALMER, Dale PORTER, Sebastien RIPOCHE, Can WANG, Youzhen WANG, Andreas WEISS, Jing XIONG, Xianglin ZHAO
  • Formylated N-heterocyclic derivatives as FGFR4 inhibitors.
    Publication number: 20190105309
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: December 5, 2018
    Publication date: April 11, 2019
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Thomas Knoepfel, Catherine Leblanc, Robert Mah
  • USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS
    Publication number: 20190076412
    Abstract: The present invention relates to therapeutic uses of compounds of formula (1) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 13, 2018
    Publication date: March 14, 2019
    Inventors: Nicole BUSCHMANN, Robin Alec FAIRHURST, Pascal FURET, Thomas KNÖPFEL, Catherine LEBLANC, Lv LIAO, Robert MAH, Pierre NIMSGERN, Sebastien RIPOCHE, Jing XIONG, Bo HAN, Can WANG, Xianglin ZHAO
  • Oxazolidin-2-one-pyrimidine derivatives and the use thereof as phosphatidylinositol-3-kinase inhibitors
    Patent number: 10202371
    Abstract: The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: February 12, 2019
    Assignee: Novartis AG
    Inventors: Robin Alec Fairhurst, Pascal Furet, Frank Stephen Kalthoff, Andreas Lerchner, Heinrich Rueeger
  • Formylated N-heterocyclic derivatives as FGFR4 inhibitors
    Patent number: 10189813
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: January 29, 2019
    Assignee: NOVARTIS AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Thomas Knoepfel, Catherine Leblanc, Robert Mah
  • New Compounds
    Publication number: 20180346465
    Abstract: The invention relates to a compound of formula (I) wherein the variables have the meaning as indicated in the claims; in free form and in salt form; and optionally the enantiomers and geometrical isomers thereof. The compounds of formula (I) are useful as therapeutic agent for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis. Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, inflammatory bowel diseases, Crohn's disease, Alzheimer's disease, leukemia, osteoarthritis, control of pruritus, chronic respiratory disease or keratoconjunctivitis in mammals.
    Type: Application
    Filed: August 6, 2018
    Publication date: December 6, 2018
    Inventors: Noelle Gauvry, Chouaib Tahtaoui, Pascal Furet, Pierre Ducray
  • Pharmaceutical combinations
    Patent number: 10130629
    Abstract: A pharmaceutical combination comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one active ingredient, as defined herein, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: November 20, 2018
    Assignee: Novartis AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Jorge Garcia Fortanet, Pascal Furet, Diana Graus Porta, Nafeeza Hafeez, Bo Han, Thomas Knoepfel, Matthew J. LaMarche, Catherine Leblanc, Lv Liao, Robert Mah, Dale Porter, Can Wang, Markus Wartmann, Jing Xiong, Xianglin Zhao
  • Compounds
    Patent number: 10059709
    Abstract: The invention relates to a compound of formula (I) wherein the variables have the meaning as indicated in the claims; in free form and in salt form; and optionally the enantiomers and geometrical isomers thereof. The compounds of formula (I) are useful as therapeutic agent for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, inflammatory bowel diseases, Crohn's disease, Alzheimer's disease, leukemia, osteoarthritis, control of pruritus, chronic respiratory disease or keratoconjunctivitis in mammals.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: August 28, 2018
    Assignee: Elanco Tiergesundheit AG
    Inventors: Noelle Gauvry, Chouaib Tahtaoui, Pascal Furet, Pierre Ducray
  • USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS
    Publication number: 20180185341
    Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof
    Type: Application
    Filed: October 2, 2015
    Publication date: July 5, 2018
    Inventors: Nicole BUSCHMANN, Robin Alec FAIRHURST, Pascal FURET, Diana GRAUS PORTA, Carolina HAEFLIGER, Bo HAN, Thomas KNÖPFEL, Catherine LEBLANC, Lv LIAO, Robert MAH, Masato MURAKAMI, Pierre NIMSGERN, Michael PALMER, Dale PORTER, Sebastien RIPOCHE, Can WANG, Youzhen WANG, Andreas WEISS, Jing XIONG, Xianglin ZHAO
  • COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1
    Publication number: 20180134695
    Abstract: The present invention relates to compounds of formula (I): in which Y, Y1, R1, R2, R3 and R4 are defined in the Summary of the Invention; capable of inhibiting the tyrosine kinase enzymatic activity of the Abelson protein (ABL1), the Abelson-related protein (ABL2) and related chimeric proteins, in particular BCR-ABL1. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.
    Type: Application
    Filed: January 10, 2018
    Publication date: May 17, 2018
    Applicant: NOVARTIS AG
    Inventors: Pascal FURET, Robert Martin GROTZFELD, Wolfgang JAHNKE, Darryl JONES, Paul William MANLEY, Andreas MARZINZIK, Xavier Francois Andre PELLE, Bahaa SALEM, Joseph SCHOEPFER
  • Use of inhibitors of the activity or function of PI3K
    Patent number: 9949979
    Abstract: The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: April 24, 2018
    Assignee: Novartis AG
    Inventors: Nigel Graham Cooke, Paulo Antonio Fernandes Gomes Dos Santos, Pascal Furet, Christina Hebach, Klemens Hoegenauer, Gregory Hollingworth, Christoph Kalis, Ian Lewis, Alexander Baxter Smith, Nicolas Soldermann, Frederic Stauffer, Ross Strang, Frank Stowasser, Nicola Tuffilli, Anette Von Matt, Romain Wolf, Frederic Zecri
  • PHARMACEUTICAL COMBINATIONS
    Publication number: 20180064709
    Abstract: A pharmaceutical combination comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one active ingredient, as defined herein, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
    Type: Application
    Filed: March 23, 2016
    Publication date: March 8, 2018
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Jorge Garcia Fortanet, Pascal Furet, Diana Graus Porta, Nafeeza Hafeez, Bo Han, Thomas Knoepfel, Matthew J. LaMarche, Catherine Leblanc
  • Formylated N-heterocyclic derivatives as FGFR4 inhibitors
    Publication number: 20180065951
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: March 23, 2016
    Publication date: March 8, 2018
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Thomas Knoepfel, Catherine Leblanc, Robert Mah
  • Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
    Patent number: 9896449
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: February 20, 2018
    Assignee: Novartis AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Thomas Knöpfel, Catherine Leblanc, Lv Liao, Robert Mah, Pierre Nimsgern, Sebastien Ripoche, Jing Xiong, Bo Han, Can Wang, Xianglin Zhao